TISIDB

Summary
Symbol	ITGAE
Name	integrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide)
Aliases	CD103; HUMINAE; HML-1 antigen; antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide; integri ......
Chromosomal Location	17p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Membrane; Single-pass type I membrane protein.
Domain	PF01839 FG-GAP repeat PF00357 Integrin alpha cytoplasmic region PF08441 Integrin alpha PF00092 von Willebrand factor type A domain
Function	Integrin alpha-E/beta-7 is a receptor for E-cadherin. It mediates adhesion of intra-epithelial T-lymphocytes to epithelial cell monolayers.

> Gene Ontology [ TOP ]
Biological Process	GO:0007229 integrin-mediated signaling pathway GO:0030198 extracellular matrix organization GO:0043062 extracellular structure organization
Molecular Function	-
Cellular Component	GO:0008305 integrin complex GO:0009897 external side of plasma membrane GO:0043235 receptor complex GO:0098552 side of membrane GO:0098636 protein complex involved in cell adhesion GO:0098802 plasma membrane receptor complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04810 Regulation of actin cytoskeleton
Reactome	R-HSA-1474244: Extracellular matrix organization R-HSA-216083: Integrin cell surface interactions

Summary
Symbol	ITGAE
Name	integrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide)
Aliases	CD103; HUMINAE; HML-1 antigen; antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide; integri ......
Chromosomal Location	17p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between ITGAE and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between ITGAE and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
26921343	Lung Carcinoma	Promote immunity (infiltration, T cell function)	Here, we used viable human lung tumor slices and autologous tumor antigen-specific T-lymphocyte clones to provide evidence that CD103 is directly involved in T-lymphocyte recruitment within epithelial tumor islets and intratumoral early T-cell signaling. Mechanistic investigations revealed that TGFβ bound to its receptors (TGFBR), which promoted the recruitment and phosphorylation of integrin-linked kinase (ILK) by TGFBR1. We further show that ILK interacted with the CD103 intracellular domain, resulting in protein kinase B (PKB)/AKT activation, thereby initiating integrin inside-out signaling.
27267849	Breast carcinoma	Promote immunity (T cell function)	CD8 status showed similar but less significant associations, but the combination of dual CD103+CD8+?TIL status was the most strongly prognostic combination for relapse-free and overall survival (HR = 0.10; 95% CI, 0.07-0.62; P = 0.006 and HR = 0.09; 95% CI, 0.07-0.57; P = 0.003, respectively). CD103 TILs are indicative of a good prognosis specifically within the basal-like subtype of breast cancer.
23188505	Epithelial tumor	Promote immunity (T cell function)	Flow-based adhesion assay showed that engagement of CD103 or LFA-1, together with TCR, enhances the strength of the T-cell/target cell interaction.
28486109	Melanoma	Promote immunity (T cell function)	Our data indicate that lack of CD103+DCs within the tumor microenvironment dominantly resists the effector phase of an anti-tumor T?cell response, contributing to immune escape.
21207371	Colon Carcinoma	Inhibit immunity (T cell function)	Here we show that CD103, an integrin mediating lymphocyte retention in epithelial tissues, is expressed at high levels on tumor-infiltrating FoxP3+ Treg in several types of murine cancer. In the CT26 model of colon cancer up to 90% of the intratumoral FoxP3+ cells expressed CD103 compared to less than 20% in lymphoid organs. CD103+ Treg suppressed T effector cell activation more strongly than CD103(neg) Treg.
28628092	Lung Carcinoma	Promote immunity	Tumors with a high density of CTLs showed enrichment for transcripts linked to tissue-resident memory cells (TRMcells), such as CD103, and CTLs from CD103hi tumors displayed features of enhanced cytotoxicity.
24190978	Ovarian Carcinoma	Promote immunity (T cell function)	Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Tumors containing CD8(+) TILs that were CD103(-) showed poor prognosis equivalent to tumors lacking CD8(+) TILs altogether. CD103(+) TILs comprise intraepithelial, activated CD8(+) T cells, and NK cells and are strongly associated with patient survival in HGSC.

Summary
Symbol	ITGAE
Name	integrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide)
Aliases	CD103; HUMINAE; HML-1 antigen; antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide; integri ......
Chromosomal Location	17p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of ITGAE in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	ITGAE
Name	integrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide)
Aliases	CD103; HUMINAE; HML-1 antigen; antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide; integri ......
Chromosomal Location	17p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of ITGAE in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.01	0.971
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.338	0.668
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.263	0.676
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.512	0.164
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.69	0.655
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.289	0.883
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.214	0.46
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.039	0.973
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.416	0.743
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.072	0.964
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.168	0.945
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.404	0.00093

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of ITGAE in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	4.1	-0.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	5.1	-1.4	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	11.8	-7	0.577
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	16.7	-16.7	0.429
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	9.1	-1.4	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	3.7	1.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	7.1	-0.9	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	ITGAE
Name	integrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide)
Aliases	CD103; HUMINAE; HML-1 antigen; antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide; integri ......
Chromosomal Location	17p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ITGAE. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	ITGAE
Name	integrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide)
Aliases	CD103; HUMINAE; HML-1 antigen; antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide; integri ......
Chromosomal Location	17p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ITGAE. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ITGAE. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	ITGAE
Name	integrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide)
Aliases	CD103; HUMINAE; HML-1 antigen; antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide; integri ......
Chromosomal Location	17p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ITGAE. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	ITGAE
Name	integrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide)
Aliases	CD103; HUMINAE; HML-1 antigen; antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide; integri ......
Chromosomal Location	17p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of ITGAE expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	ITGAE
Name	integrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide)
Aliases	CD103; HUMINAE; HML-1 antigen; antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide; integri ......
Chromosomal Location	17p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between ITGAE and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	ITGAE
Name	integrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide)
Aliases	CD103; HUMINAE; HML-1 antigen; antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide; integri ......
Chromosomal Location	17p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting ITGAE collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse ITGAE